Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage biotechnology company in immuno-oncology, and the news flow around SNSE reflects its focus on cancer drug development, clinical data, and corporate strategy. The company regularly issues press releases on quarterly financial results, clinical trial milestones, capital markets actions, and strategic decisions, which are then furnished to the SEC on Form 8-K.
Recent news has centered on solnerstotug, Sensei’s lead product candidate. The company has released updates from a multi-center Phase 1/2 trial evaluating solnerstotug, a conditionally active antibody targeting the VISTA checkpoint, as monotherapy and in combination with Libtayo® (cemiplimab) in patients with advanced solid tumors. These announcements have highlighted emerging clinical signals in PD-(L)1 resistant “hot” tumors, durability of progression-free survival, safety and tolerability data, and presentations at major scientific meetings such as the ESMO Congress.
Investors following SNSE news also see corporate and financial updates, including quarterly earnings releases, commentary on research and development and general and administrative expenses, and disclosures about cash, cash equivalents, and marketable securities. Sensei has additionally reported participation in investor and scientific conferences, such as healthcare and oncology events where company representatives discuss its tumor microenvironment–focused approach.
A key development in the company’s news stream is the strategic review announced on October 30, 2025, when Sensei’s Board decided to discontinue development of solnerstotug and explore strategic alternatives that may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. Subsequent news has described workforce reductions and the company’s intention to retain a smaller team to manage this process and maintain regulatory and financial reporting compliance.
This news page allows readers to track these evolving themes: clinical data releases, financial results, Nasdaq listing and reverse stock split actions, and updates on the strategic alternatives process, all of which shape the ongoing story of SNSE.
Sensei Biotherapeutics (NASDAQ: SNSE) announced that CEO John Celebi will participate in a fireside chat at the Berenberg virtual U.S. CEO Conference on November 9, 2021, at 10:00 a.m. EST. The event will be accessible via a live audio webcast on the company’s website, with a replay available for 90 days afterward. Sensei focuses on developing next-generation immunotherapies for cancer, leveraging its unique TMAb™ and ImmunoPhage™ platforms, including the therapeutic candidate SNS-101 targeting immune checkpoint VISTA and the ImmunoPhage cocktail SNS-401-NG for Merkel Cell Carcinoma.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its presentation of preclinical data for its anti-VISTA candidate, SNS-101, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The data will mark the first scientific presentation from Sensei's TMAb platform, which aims to enhance immune checkpoint therapies through tumor microenvironment selectivity. SNS-101 targets VISTA, a crucial immune checkpoint, to potentially boost anti-cancer immune responses while minimizing side effects.
Sensei Biotherapeutics (NASDAQ: SNSE) reported financial results for Q2 2021, highlighting significant developments in its SNS-VISTA program, which showed notable anti-tumor activity. The company aims to select a lead candidate and begin IND-enabling studies by year-end 2021. As of June 30, 2021, Sensei maintained a strong cash position of $162.5 million, expected to fund operations into 2024. However, the company experienced increased R&D expenses of $5.9 million and a net loss of $9.8 million, reflecting higher operational costs.
Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Kristian Humer as an independent director, effective July 30, 2021. Humer, who joins from Viridian Therapeutics, brings over 20 years of experience in life sciences investment banking. The company’s CEO, John Celebi, expressed confidence in Humer's expertise to guide the firm through its growth phase as a public company. Sensei Biotherapeutics is focused on developing next-generation cancer immunotherapies, leveraging innovative platforms such as ImmunoPhage and TMAb.
Sensei Biotherapeutics is shifting its focus towards developing next-generation phage product candidates, including SNS-401-NG and SNS-VISTA, while discontinuing the SNS-301 program due to suboptimal clinical findings. The decision was driven by an analysis that revealed insufficient T-cell activation. This strategic pivot extends the company's cash runway into the first half of 2024, supporting ongoing operations. Sensei plans to initiate IND-enabling studies for SNS-401-NG by late 2022 and share comprehensive SNS-301 data at a future scientific conference.
Sensei Biotherapeutics reported promising results from its Phase 1/2 trial of SNS-301, an investigational therapy for advanced squamous cell carcinoma of the head and neck. Data shows that SNS-301 combined with pembrolizumab demonstrated a favorable safety profile and a potential for durable tumor responses. Notably, one patient experienced a 71% tumor reduction lasting 11 months. The company expects to provide updated data, including frontline therapy results, by year-end, enhancing the understanding of its proprietary ImmunoPhage platform.
Sensei Biotherapeutics (NASDAQ: SNSE) reported strong progress in Q1 2021, highlighting advancements in its ImmunoPhage™ platform and the VISTA program. The company has commenced patient dosing in a Phase 1/2 study of SNS-301 for squamous cell carcinoma, with data accepted for presentation at ASCO 2021. Sensei ended the quarter with $169.4 million in cash, ensuring funding through at least mid-2023. The recent IPO raised $152.6 million, which will support ongoing and future research initiatives.
Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Dr. Maura Gillison and Dr. Richard Ulevitch to its Immuno-Oncology Advisory Board. Dr. Gillison, an expert in head and neck cancers, and Dr. Ulevitch, a leader in innate immunity, bring extensive knowledge to the company's strategic direction. Their insights aim to enhance the potential of the ImmunoPhage™ platform and foster collaboration among advisors to drive advancements in cancer treatment. This move is seen as a step towards bolstering Sensei's capabilities in developing innovative immunotherapies.
Sensei Biotherapeutics announces the appointment of Dr. Jessie M. English to its Board of Directors, bringing over 20 years of oncology research and leadership experience. Her expertise will enhance the company's ability to develop next-generation immunotherapies, including its proprietary ImmunoPhage™ platform. Dr. English previously led Tilos Therapeutics, acquired by Merck, and has held significant roles in major biotech firms. This leadership change aims to strengthen Sensei's clinical programs and support its vision during a critical development phase.
Sensei Biotherapeutics reports a strong financial foundation following its successful upsized IPO in February 2021, raising approximately $152.6 million. The company expects to release substantial data from the ongoing Phase 1/2 study of SNS-301 for treating advanced head and neck cancer by year-end. In 2020, Sensei increased R&D expenses to $11.9 million and G&A expenses to $7.5 million, resulting in a net loss of $20.1 million. Sensei was also added to the Russell 2000 Index on March 22, 2021, reflecting its growing market presence.